Gastric and gastro-esophageal cancers (GC/GEJ) appear as the second cancer-related death worldwide. Diagnosis is made at an advanced stage offering a curative
attempt in less than 50% of cases. Despite the improvements of the systemic cytotoxic
chemotherapy regimens, the prognosis of patients with metastatic GC/GEJ cancer
remains poor. Recent insights in biochemical pathways have permitted to identify
potential targets. The extracellular domain of HER2 receptors is implicated in cells’
proliferation and in the anti-apoptotic process occurring in GC/GEJ cancers. Trastuzumab,
a monoclonal antibody targeting HER2, in addition to chemotherapy permitted
to obtain more than one year of survival in HER2-positive advanced GC/GEJ cancers.
Recently, ramucirumab, a humanized monoclonal antibody targeting VEGFR-2
receptor demonstrated its efficacy as a second line treatment for patients with advanced GC/GEJ cancer.
These encouraging results have justified evaluating targeted therapies in GC/GEJ cancers. In this review,
we summarize targeted therapies that might present clinical efficacy in the treatment of advanced
Keywords: Gastric carcinoma, gastric cancer, targeted therapy, anti VEGF, anti EGFR, trastuzumab.
Rights & PermissionsPrintExport